COMMUNIQUÉS West-GlobeNewswire

Imprivata, éditeur international de solutions de gestion des accès, se développe sur le marché français pour répondre à la demande croissante en matière de sécurité et de conformité
18/09/2025
Initialement axées sur les soins de santé, les solutions Imprivata permettent un accès clinique rapide et sécurisé aux services informatiques afin de soutenir le programme CaRE et en particulier le domaine HospiConnect [...]
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
18/09/2025
Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with [...]
89bio, Inc. Announces Agreement to be Acquired by Roche
18/09/2025
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash [...]
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
18/09/2025
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesity Acquisition [...]
Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets
18/09/2025
Press Release 42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022) 25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission [...]
Climat : la Science Based Targets initiative (SBTi) valide les objectifs à court terme d’EUROAPI
18/09/2025
Communiqué de presse Réduction de 42% des émissions de gaz à effet de serre des Scopes 1 et 2 d’ici à 2030 (par rapport à 2022) Réduction de 25% des émissions de gaz à effet de serre du Scope 3 d’ici à 2030 (par rapport [...]
Fangzhou Named ‘Outstanding Growth Story in Hong Kong Stocks’ at China Capital Market Development Forum 2025
18/09/2025
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, was recognized as an “Outstanding Growth Story in Hong Kong [...]
EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future
18/09/2025
EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future The two companies continue to grow their wearables lineup with new products revealed at Meta [...]
EssilorLuxottica: Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur
18/09/2025
Le partenariat EssilorLuxottica et Meta se poursuit avec de nouvelles lunettes avec IA qui préfigurent le futur Les deux groupes élargissent leur gamme de « wearables » avec de nouveaux produits dévoilés lors de Meta [...]
Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management
18/09/2025
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“ [...]
Aurora Spine Announces Launch of its DEXA-L™ Anterior Lumbar Interbody Fusion Device
18/09/2025
Please click here to view image CARLSBAD, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional [...]
NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1
17/09/2025
Les données ont montré un profil de sécurité favorable et des signaux préliminaires d’efficacité dans une population lourdement prétraitée dont le cancer était en progression malgré plusieurs lignes de traitement, [...]
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
17/09/2025
Atlanta, GA, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced it has completed the repurchase of 366,359 shares [...]
Vaxart Appoints W. Mark Watson as Lead Independent Director
17/09/2025
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
17/09/2025
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Are Women on the Frontline of Antimicrobial Resistance?
17/09/2025
LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- National Patient Survey of Women’s Urinary Tract Infection (UTI) and Prenatal Screening reveals women suffering from UTI concerned about immediate antibiotic prescribing and [...]
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
17/09/2025
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy ® ) achieved significant weight loss, with one in three study participants losing 20% or more body weight 1 ** Oral semaglutide 25 mg also demonstrated [...]
Bionano Genomics, Inc. Announces Closing of $10 Million Public Oﬀering
17/09/2025
SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 [...]
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years
17/09/2025
WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of [...]

Pages